TOMSK, RUSSIA / RankWire.AI / – Russian researchers have engineered and evaluated a bioactive layer for titanium orthopedic devices. The innovative material incorporates calcium phosphate derived from hydroxyapatite and includes nitrogen compounds associated with nitric oxide generation. In laboratory experiments, human mesenchymal stem cells demonstrated improved viability on coated titanium compared to untreated metal. The team also analyzed surface chemistry, hardness, thickness, and wettability. The peer-reviewed research concentrated on how different gas mixtures altered the coating’s properties and biological responses.
At Tomsk Polytechnic University, scientists fabricated the coatings via reactive magnetron sputtering within a vacuum chamber. They employed a hydroxyapatite target and modified the nitrogen-to-argon ratio during the deposition process. The study tested five gas atmospheres, including pure nitrogen and pure argon, noting measurable variations in the coating’s characteristics. Surface structure, chemical makeup, mechanical strength, and liquid contact angle were all evaluated. Subsequently, the coated titanium samples were exposed to human mesenchymal stem cells under controlled laboratory conditions.
Findings indicated that argon concentration affected several physical attributes of the coatings. Increased argon levels resulted in thicker, denser, and harder layers. Chemical analyses revealed bonds between nitrogen-carbon and nitrogen-oxygen on the modified surfaces. Cell survival rates on coated samples were compared to those on untreated titanium, with coated surfaces showing notably higher cell viability throughout the experiment. Additionally, gene expression related to early bone-cell differentiation was monitored to understand the influence of the coatings on cell behavior.
Enhanced titanium coatings promote greater cell viability
The study demonstrated that elevated nitrogen levels affected the activity of certain genes involved in early osteogenic differentiation, with effects becoming evident after seven days of cell culture. Despite these genetic changes, the cells retained their capacity to produce bone-like tissue. The research did not involve testing in human subjects, nor did it measure clinical outcomes from actual implants. Consequently, the findings are limited to laboratory settings and do not yet confirm clinical benefits for patients requiring joint replacements or other orthopedic procedures.
The biomedical evaluation was carried out by scientists from Immanuel Kant Baltic Federal University and Siberian State Medical University, with additional contributions from researchers at Saint Petersburg State University. The investigation explored how variations in coating composition influence both material performance and cellular responses. Hydroxyapatite, due to its calcium phosphate structure, closely resembles the mineral part of human bone and is frequently studied for medical applications. The researchers maintained this base material while altering nitrogen exposure during the coating process.
Future investigations will focus on long-term biological impacts
Following the initial seven-day tests, the team plans further laboratory and biological assessments. These will include observing stem cells over periods ranging from 10 to 28 days, as well as evaluating the rate at which the coatings dissolve. Additional experiments will aim to measure nitric oxide release into surrounding tissues in vivo. Such studies were not part of the published work. Present results remain confined to laboratory measurements and controlled cell experiments on coated titanium samples.
This research contributes new data on how different nitrogen and argon ratios influence calcium phosphate coatings on titanium implants. Variations in coating thickness, density, hardness, chemical bonds, and cellular responses were documented. Consistently, the coated samples supported significantly better stem-cell survival compared to untreated titanium under test conditions. It is important to note that the study remains preclinical; it does not establish safety or effectiveness in human patients. Further research is necessary to explore aspects such as long-term cell behavior and nitric oxide release that were not addressed in the current laboratory work.